Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Bevacizumab-Refractory Glioblastoma
NCT02478164Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in glioblastoma (GBM), sponsored by Dana-Farber Cancer Institute. Started Jul 2015; status: completed.
02
Drugs
ponatinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02478164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478164.